tradingkey.logo

BRIEF-Harmony Biosciences Provides Update On The Status Of The Supplemental New Drug Application For Pitolisant In Idiopathic Hypersomnia

ReutersFeb 19, 2025 3:22 PM

- Harmony Biosciences Holdings Inc HRMY.O:

  • HARMONY BIOSCIENCES PROVIDES UPDATE ON THE STATUS OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR PITOLISANT IN IDIOPATHIC HYPERSOMNIA

  • HARMONY BIOSCIENCES HOLDINGS INC - 2025 NET REVENUE GUIDANCE REMAINS UNCHANGED AT $820-$860 MILLION

  • HARMONY BIOSCIENCES HOLDINGS INC - TO INITIATE PHASE 3 TRIAL OF PITOLISANT HD IN Q4 2025

  • HARMONY BIOSCIENCES HOLDINGS INC - RECEIVES FDA REFUSAL TO FILE LETTER FOR PITOLISANT

  • HARMONY BIOSCIENCES -ON TRACK TO INITIATE A PHASE 3 REGISTRATIONAL TRIAL OF PITOLISANT HD IN IH IN Q4 2025, WITH A TARGET PDUFA DATE IN 2028

Source text: ID:nBw4VR77Na

Further company coverage: HRMY.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI